Kadmon (KDMN) Raised to Buy at ValuEngine
ValuEngine upgraded shares of Kadmon (NYSE:KDMN) from a hold rating to a buy rating in a report issued on Wednesday.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research downgraded Kadmon from a buy rating to a hold rating in a research report on Thursday, October 11th. HC Wainwright set a $25.00 target price on Kadmon and gave the company a buy rating in a research report on Monday, August 13th. Finally, WBB Securities upgraded Kadmon from a sell rating to a hold rating and set a $2.90 target price on the stock in a research report on Wednesday, October 17th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $11.43.
Shares of KDMN stock opened at $2.64 on Wednesday. The company has a market cap of $304.24 million, a price-to-earnings ratio of -1.86 and a beta of 3.57. Kadmon has a 12-month low of $1.88 and a 12-month high of $5.86.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AE Wealth Management LLC lifted its position in shares of Kadmon by 3.7% in the second quarter. AE Wealth Management LLC now owns 529,212 shares of the company’s stock valued at $2,112,000 after acquiring an additional 18,750 shares in the last quarter. American International Group Inc. lifted its position in shares of Kadmon by 46.2% in the third quarter. American International Group Inc. now owns 66,148 shares of the company’s stock valued at $221,000 after acquiring an additional 20,894 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Kadmon in the first quarter valued at approximately $106,000. Voya Investment Management LLC purchased a new position in shares of Kadmon in the second quarter valued at approximately $101,000. Finally, Metropolitan Life Insurance Co. NY purchased a new position in shares of Kadmon in the second quarter valued at approximately $105,000. Institutional investors and hedge funds own 69.65% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
See Also: Diversification
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.